Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

38

Revenue 2017

Imbruvica

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.

Cancer drugs and China sustain AZ’s return to growth

Cancer drugs and China sustain AZ’s return to growth

BTK inhibitor Calquence (acalabrutinib) – a rival to Johnson/AbbVie's big-selling Imbruvica (ibrutinib) – could be filed for chronic lymphocytic leukaemia (CLL) before year-end extending its current use in mantle

Imbruvica and Gazyvo approved in first non-chemo CLL use

Imbruvica and Gazyvo approved in first non-chemo CLL use Imbruvica is co-marketed by J&J and AbbVie, the companies announcing full year revenues of $2.61bn and $3.59bn respectively in the recent Q4 results. ... In just a few years, Imbruvica has become an important treatment for chronic lymphocytic leukaemia.

European biosimilars hit AbbVie’s Humira revenues in Q4

European biosimilars hit AbbVie’s Humira revenues in Q4 This portfolio revenue rose steeply to $3.93bn, up 45% on a reported basis, driven by a near 40% increase in Imbruvica sales (to $3.59bn), while Venclexta revenues hit $344m ... However just last week AbbVie suffered a knock to its ambitions for

J&J earnings top expectations, but feels the squeeze in US

J&J earnings top expectations, but feels the squeeze in US Nevertheless, the company's annual revenues rose almost 7% to $81.6bn, driven up by three rising star performers in particular: psoriasis treatment Stelara, leukaemia drug Imbruvica and multiple myeloma Darzalex.

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly adds to pharma M&A run with $8bn Loxo buy-out s Imbruvica.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics